Cure MSA

Country specific patient information


Principal investigator:
Prof. Joaquim Ferreira

Faculdade de Medicina da Universidade de Lisboa
Instituto de Medicina Molecular
Lisbon, Portugal

Expertise of the participating organization:

Our team is composed of clinical neurologists (4), clinical pharmacologists (1), research fellows (3) and a manager (1). The team has been devoted to the treatment and research of movement disorders since its inception 5 years ago. The actual team is quite young but was built on the experience of more than 25 years of research activity, particularly in Movement disorders field, in our teaching hospital (Department of Neurology- Hospital de Santa Maria, Lisboa, Portugal). In fact the outpatient clinic specialised in Movement disorders exists in our Neurology department since 1973. Nowadays the team expertise in Movement disorders is internationally recognised. The following are the main activities where the team is engaged:
1. Care of movement disorders patients in out-patient and in-patient settings;
2. Long-term clinical trials in Parkinson's disease and dystonia:
3. Research programme on epidemiology; clinical pharmacology and treatment of focal dystonias;
4. Co-ordination and organisation of the movement disorders Cochrane review group (the base unit is located in our department);
5. Research activities related with the secondary analysis (quality assessments, systematic reviews, clinimetrics of rating scales) of movement disorders literature.

Recent publications relevant to the EMSA-SG:

Brum M, Reimao S, Sousa D, de Carvalho R, Ferreira JJ. Spinal Cord Lesion by Minor Trauma as an Early Sign of Multiple System Atrophy. Front Neurol 2016;7:33.


Ferreira JJ, Almeida L, Cunha L, Ticmeanu M, Rosa MM, Januario C, et al. Effects of nebicapone on levodopa pharmacokinetics, catechol-O-methyltransferase activity, and motor fluctuations in patients with Parkinson disease. Clin Neuropharmacol 2008; 31: 2-18.


Ferreira J, Silva JM, Freire R, Pignatelli J, Guedes LC, Feijo A, et al. Skin cancers and precancerous lesions in Parkinson's disease patients. Mov Disord 2007; 22: 1471-5. 


Ferreira JJ, Guedes LC, Rosa MM, Coelho M, van Doeselaar M, Schweiger D, et al. High prevalence of LRRK2 mutations in familial and sporadic Parkinson's disease in Portugal. Mov Disord 2007; 22: 1194-201.


Di Fonzo A, Tassorelli C, De Mari M, Chien HF, Ferreira J, Rohe CF, et al. Comprehensive analysis of the LRRK2 gene in sixty families with Parkinson's disease. Eur J Hum Genet 2006; 14: 322-31. 


Ferreira JJ, Desboeuf K, Galitzky M, Thalamas C, Brefel-Courbon C, Fabre N, et al. Sleep disruption, daytime somnolence and 'sleep attacks' in Parkinson's disease: a clinical survey in PD patients and age-matched healthy volunteers. Eur J Neurol 2006; 13: 209-14. 


Di Fonzo A, Rohe CF, Ferreira J, Chien HF, Vacca L, Stocchi F, et al. A frequent LRRK2 gene mutation associated with autosomal dominant Parkinson's disease. Lancet 2005; 365: 412-5.


Sampaio C, Ferreira JJ, Costa J. Evidence-based medicine (EBM) applied to Parkinson's disease treatment. Parkinsonism Relat Disord 2002; 9: 7-13.